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2.1 The burden of metabolic disease in Germany and Europe as a whole 
 
Metabolic diseases, including dyslipidemia, obesity, type 2 diabetes mellitus (T2DM), and 
hypertension, are a major public health problem. It is estimated that at least 26% of the adult 
population in Germany have obesity while 28% have high blood pressure [1]. Although the 
prevalence of raised blood pressure has decreased over the past two decades in Germany, the 
prevalence of obesity has continued to steadily increase [1], and dyslipidemia has an even higher 
prevalence of approximately 65% in adults under 80 years old [2]. At the same time, prevalence 
of T2DM has increased by more than 50% in many European countries over the past decade [3]. 
In Germany, it is currently estimated that at least 7.2%-9.9% of the adult population is living with 
diabetes, and these numbers continue to grow [4, 5]. Recent estimates predict an increase in T2DM 
prevalence of 54-77% in Germany between the years 2015 and 2040, meaning that between 10 
and 12 million people could be living with T2DM in Germany in the next 20 years [4].  
Metabolic diseases are complex, stemming from a number of both modifiable and unmodifiable 
factors that are often intertwined. Several major modifiable risk factors are poor diet, smoking, 
and inadequate physical activity [6-9]. However, metabolic diseases themselves are also risk 
factors for the development of cardiovascular disease (CVD), which is a leading cause of morbidity 
and mortality worldwide (Figure 1) [1, 7, 10, 11]. In Europe as a whole, CVD causes over 3.9 
million deaths each year, or 45% of all deaths, and it has been estimated that CVD costs the 
European Union €210 billion a year [3]. In Germany specifically, CVD is estimated to have 
accounted for 37% of deaths in 2016 [1]. Although age-standardized mortality rates from CVD in 
Europe have declined over the past few decades, absolute numbers have climbed along with the 




Figure 1: A simplified schema of the relationship between cardiovascular disease, metabolic diseases, and their major 
risk factors. The metabolic diseases and risk factors that are the focus of this dissertation are highlighted in blue. 
Arrows indicate the directionality of each relationship. T2DM: Type 2 diabetes mellitus. 
 
It was recently determined that high blood pressure was the top medical risk factor for death due 
to both CVD worldwide between 1980 and 2010, responsible for at least 40% of these deaths [12]. 
An additional 15% of these deaths could be attributed to overweight/obesity and elevated blood 
glucose each, and high serum cholesterol was estimated to be responsible for an additional 10% of 
CVD and T2DM deaths [12], while another source estimated that altered lipoprotein metabolism 
represents approximately half of the population-attributable risk of CVD [11]. As a result, 
interventions that favorably modify major metabolic risk factors at the population level stand to 
reduce the burden of both metabolic and cardiovascular diseases enormously. However, despite 
intense research focus and public health efforts in the past decades, the prevalence of metabolic 
diseases continues to rise, and a deeper understanding of the risk factors implicated in the 





2.2 Nutrition as a major modifiable risk factor 
 
Nutrition is a major modifiable risk factor for both metabolic diseases and CVD. While raised 
systolic blood pressure is considered the largest medical contributor to CVD mortality across 
Europe, nutrition is the largest behavioral contributor, responsible for an estimated 49.2% of all 
CVD deaths [3, 6]. Diet is also one of the most important modifiable risk factors for many 
metabolic diseases. Along with increased physical activity, nutrition therapy is the cornerstone of 
prevention and treatment of obesity. Additionally, several dietary factors, most notably sodium 
and potassium, are involved in the regulation of blood pressure; a low-sodium, high-potassium 
diet in particular has been shown to be effective in reducing the risk for hypertension [13].  
Furthermore, it has been estimated that lifestyle changes, such as weight loss, dietary 
modifications, and increased physical activity, can provide a 40%-70% reduction in relative risk 
of the progression from prediabetes to T2DM and may delay or prevent the development of 
diabetes-related comorbidities [14-18]. Nutrition therapy for T2DM has also been demonstrated 
to lower hemoglobin A1c (HbA1C) levels by 1-2 HbA1c percentage points on average, as well as 
resulting in weight loss, improved lipid levels, and lower blood pressure [9, 14]. A number of 
studies have also confirmed that dietary intervention is an effective non-pharmaceutical strategy 
for improving serum lipid levels [19, 20].  
Suboptimal diet has consistently been associated with the development and progression of 
metabolic diseases, for example by raising blood glucose levels, leading to the derangement of 
serum lipid levels, raising blood pressure, or contributing to excess body weight and increased 
inflammation [8, 20]. In the past, macronutrient distribution was a main cornerstone of dietary 
recommendations for the prevention and treatment of metabolic diseases. Due to the evidence for 
a relationship between high saturated fat and cholesterol intake and a higher risk for dyslipidemia 
and metabolic dysfunction, a low fat, moderate carbohydrate diet was promoted [21, 22]. However, 
recent studies point to a differential association between dietary fat and metabolic diseases or 
biomarkers. While the fat content of a diet itself is not consistently related to metabolic diseases/ 
biomarkers, replacing saturated fat with polyunsaturated fats is often associated with reduced risk, 
while replacing saturated fats with carbohydrates (especially refined carbohydrates) has no effect 
or even increases risk [21, 23, 24]. Additionally, although a low-fat, moderate-carbohydrate diet 
with caloric restriction has also long been recommended for prevention and treatment of metabolic 
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diseases, a number of recent studies show a low-carbohydrate, high fat diet may be equally 
effective in managing blood glucose control and weight loss, at least in the short term [25-27].  
Further research has also identified a number of foods and nutrients associated with metabolic 
diseases. In general, diets high in fruits and vegetables, whole grains, unsaturated (especially 
omega-3) fats, nuts and legumes have consistently been inversely associated with inflammation 
and metabolic diseases [8, 20, 28, 29]. These foods closely align with dietary patterns such as the 
Mediterranean diet, DASH diet, or a plant-based diet, which have also shown great promise in 
preventing and treating metabolic diseases [20, 30-32].  
Conversely, a “Western” diet, high in processed foods, red meats, refined grains, excess sodium, 
saturated fat, alcohol and added sugars, promotes inflammation and has been positively associated 
with the development of metabolic diseases [8, 20, 33, 34]. As a result, the current focus in 
nutrition research has shifted away from macronutrient composition alone and has been placed 
more on individual foods, nutrients, and increasingly, dietary patterns.  
It is clear that a full understanding of how individual foods and nutrients, dietary patterns, and the 
quantity and quality of macronutrients are related to metabolic diseases is crucial to making useful 
and effective recommendations for public health measures. Because nutrition is strongly 
associated with metabolic biomarkers and outcomes, it is a major target for behavioral 
modification and offers huge potential in the prevention and treatment of metabolic diseases. It 
was recently estimated that nearly half (45.4%) of all cardiometabolic deaths in the United States 
could be attributed to suboptimal diet, and that suboptimal diet is responsible for over 18% of all 
T2DM, ischemic heart disease, and stroke costs in the United States, translating to $50.4 billion 
per year [35, 36]. Consequently, well-informed dietary recommendations (along with public 
adherence) could translate to a major reduction in metabolic disease-related morbidity, mortality 





2.3 The role of the gut microbiota and fecal metabolome in metabolic diseases 
 
The human gut microbiome has become an area of immense research interest in recent decades 
[37]. It has been associated with various disease states, ranging from obesity to irritable bowel 
disease to rheumatoid arthritis and T2DM [38-42]. The composition of the gut microbiome is 
influenced by a number of factors such as age, geography, medications, diet, and even mode of 
delivery at birth [37, 43, 44]. The gut microbiome plays an integral role in host health and 
regulating host physiology [45]. The gut microbiota aid in the digestion and absorption of nutrients 
and produce a wide range of metabolites and even vitamins [46, 47]. Subsequently, the 
composition and activity of the gut microbiota plays a large role in determining the composition 
of the fecal metabolome [48].  
At the same time, nutrition inevitably plays a major role in shaping gut microbiota composition as 
the main source of substrate for microbes residing within the gastrointestinal tract [49-52]. A diet 
rich in certain nutrients selects for microbes that preferentially utilize them as substrates. 
Additionally, the presence or absence of certain microbes may impact the effect a dietary 
component exerts on the host. Although nutrition is independently a major risk factor for metabolic 
diseases, the gut microbiota (and the metabolites it produces) appears to be one way by which diet-
disease associations are mediated (Figure 2) [53]. Probably the most well studied example of this 
is the fermentation of dietary fiber in the gut. Dietary fiber is associated with a number of favorable 
health outcomes, though it is resistant to digestion by the host. While some benefits may be 
mechanical, such as increased bulk, potentially leading to increased satiety and decreased intestinal 
transit time, others are a result of short-chain fatty acids (SCFA), mainly butyrate, acetate, and 
propionate, which are metabolites produced a result of the fermentation of dietary fiber by SCFA-
producing bacteria [46]. SCFA aid in maintaining an ideal pH in the colon, maintain barrier 
function, have anti-cancer properties, and are absorbed into the bloodstream and play a role in 




Figure 2: The relationship between diet, the gut microbiome, the fecal metabolome and metabolic health, as examined 
in this dissertation. Diet affects the composition of the gut microbiota and in turn, the metabolites it produces, many 
of which affect metabolic health. However, diet has also been independently associated with metabolic health. Arrows 
indicate the directionality of each relationship.  
 
Another example is the conversion of dietary phosphatidylcholine or L-carnitine to 
Trimethylamine (TMA) by gut microbiota. TMA is the precursor to Trimethylamine N-oxide 
(TMAO), which has been associated with the development of atherosclerotic lesions and the risk 
of CVD, though some studies have been conflicting and research continues in this area [53, 55]. 
The gut microbiota play an essential role in the conversion of phosphatidylcholine to TMAO, and 
as a result, the observed associations between TMAO and CVD. Additionally, the gut microbiota 
has also been associated with metabolic diseases independently of diet. For example, bile acid-
modifying gut bacteria play an important role in modulating lipid metabolism by converting 
primary to secondary bile acids, which act as signaling molecules and which also results in 
increased excretion and de novo production of bile acids [53, 56, 57]. The de novo production of 
bile acids depletes the body’s cholesterol stores and may therefore lower serum cholesterol levels. 
Additionally, bile acids modulate lipid metabolism by binding to intestinal and hepatic farnesoid 
X receptor (FXR) [58]. 
However, despite intensive research into the gut microbiome and human health in recent years, it 
is still not clear what a “healthy” microbiota composition is or how to best modify the gut 
microbiome favorably for disease prevention or treatment [46, 59]. In addition to high inter-
individual variability in gut microbiota composition, another complicating factor is functional 
redundancy, meaning that multiple taxa within an environment may perform similar roles [59]. As 
a result, the microbiota composition of two individuals could look very different while fulfilling 
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the same functions. Furthermore, the best strategy to assess microbiota composition in relation to 
health remains controversial. More and more, researchers are analyzing the fecal metabolome in 
addition to or even instead of microbiota composition, therefore assessing the functions of an 
individual’s microbiota based on the metabolites it produces, rather than only assessing the 
composition of the microbes themselves [48]. Still, many unanswered questions remain in this 
field, and further study into the relationship between diet, the gut microbiome, and metabolic 
diseases is essential. 
 
2.4 Scientific challenges 
While the areas of nutrition, the gut microbiome, and metabolic diseases have been the subject of 
extensive research, there are many questions that remain unclarified. Associations between diet 
and metabolic diseases are often conflicting, and dietary recommendations for the prevention and 
treatment of metabolic diseases have changed distinctly in recent decades [22, 23, 28]. 
Furthermore, the etiology of metabolic diseases is still not completely understood, despite decades 
of research in this area. Although it seems clear that dysbiosis of the gut microbiota plays some 
role in metabolic disease risk, the depth of its role remains poorly understood. Associations 
between the gut microbiota and metabolic risk factors and disease have been identified in several 
studies, but associations found between individual taxa and disease states are often conflicting [53, 
54]. The degree to which associations between nutrition and metabolic diseases are mediated by 
the gut microbiome also requires further investigation. Furthermore, the best strategy for assessing 
disease risk based on gut microbiota composition remains undecided. There are countless methods 
in use for describing and analyzing gut microbiota composition and its associations with various 
disease states. These efforts are complicated by the high complexity, sparsity, and of 
compositionality of microbiome data, as well as by functional redundancy and that taxa can 
frequently not be reliably identified beyond the genus level due to the methods currently used in 
many microbiome studies.  
Although nutrition and the gut microbiota has been studied extensively, many findings have not 
yet been confirmed in population-based studies with large sample sizes. The same problem persists 
for studies on gut microbiota and metabolic diseases. Sufficient studies combining detailed data 
on habitual diet, gut microbiota composition, and metabolic disease risk in one joint analysis are 
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also lacking, and even fewer studies analyzing fecal metabolites in this context exist. Although it 
is clear that these factors are involved in the development of metabolic diseases, the extent to 
which both the gut microbiome and/or fecal metabolites play a role in modifying the association 
between diet and metabolic diseases remains unclear.  
 
2.5 Aims and objectives of the Dissertation 
 
The aim of this dissertation is to address the previously specified gaps in the literature by analyzing 
the role of habitual diet, the gut microbiota, and fecal metabolites in the development of metabolic 
diseases in a large, well-defined, population-based cohort. The dissertation is based on two first-
author publications of the doctoral candidate, both of which have been published in international 
journals and were peer reviewed. The first publication focused on fecal metabolites and serum 
lipids, while the second publication investigated both habitual diet and the gut microbiota in the 
context of metabolic diseases (serum lipids, BMI, waist circumference, hypertension, and T2DM). 
The first publication aimed to identify a relationship between selected fecal metabolites and 
biomarkers of dyslipidemia. The aims of second publication were 1) to identify an appropriate 
method for dimensionality reduction of the available gut microbiota data, 2) to identify differential 
associations of food items with microbial subgroups and 3) to examine the relationship between 
microbial subgroups and metabolic diseases.  
 
2.6 Description of the analyses and contribution to the problem at hand 
 
The first publication examined the relationship between fecal metabolites and markers of 
dyslipidemia in 1,387 participants of the KORA FF4 study, which was conducted in 2013/2014 in 
the Augsburg region as the second follow-up to the original KORA S4 study. Twenty-five fecal 
metabolites were selected from over 800 available metabolites based on their previously identified 
associations with diet and dyslipidemia in the literature. The selected metabolites, which belong 






Two sets of Dirichlet regression models were used to evaluate associations between the selected 
variables: one assessing associations between dietary factors and the 20 subgroups, and another 
assessing the associations between metabolic diseases and the 20 subgroups. This publication 
was able to confirm existing associations between diet and the gut microbiota, as well as 
associations between metabolic diseases and the gut microbiota, in a large, population-based 
study. Additionally, it identified a number of new associations that should be explored further in 
future studies. Finally, the publication presented a promising method for the assessment of gut 
microbiota composition in relation to diet and human health, and which holds promise for the 





Metabolic diseases are a major public health challenge both in Germany and worldwide. With 
increasing life expectancy and decreasing birth rates, the population of Germany is aging, leading 
to an increased burden of metabolic diseases. Nutrition is an important modifiable risk factor of 
metabolic diseases and has been the focus of research and public health interventions for decades. 
However, official recommendations have been conflicting, and while the basics of a preventative 
diet seem clear, specific questions remain unanswered and the mechanisms behind diet-disease 
associations often remain uncertain. The gut microbiome and metabolome have emerged as a 
major focus of research in recent decades as it becomes clear that dysbiosis of the gut microbita is 
associated with a wide range of human diseases. However, exactly how important the composition 
and function of the gut microbiota and its metabolites are to metabolic health remains elusive, and 
many questions still remain. Furthermore, many previously identified associations have not been 
validated in large cohort studies. 
This dissertation, which encompasses two publications, aims to gain new insight into the 
complicated relationship between habitual diet, the gut microbiome, and metabolic diseases, while 
also confirming previously identified associations in a large, population-based study. The analyses 
from both publications included in the dissertation use data from the Cooperative Health Research 
in the Region of Augsburg (KORA FF4) study, conducted in 2013/2014, in which 2,279 
participants of the original S4 study (1999-2001, n=4,261) returned for a second follow-up survey.  
The first publication investigated the relationship between selected fecal metabolites and serum 
lipid levels in 1,387 participants of the KORA FF4 study. Metabolite concentrations were 
measured and identified by Metabolon Inc (Durham, NC, USA). Plant and animal sterols, as well 
as primary and secondary bile acids were selected from the set of 807 metabolites. Serum LDL-
cholesterol, HDL-cholesterol, total cholesterol, and triglycerides were selected as outcome 
variables to represent dyslipidemia. All four variables were analyzed both as continuous variables 
and as binary variables with cutoffs for the binary variables chosen according to the 2003 National 
Cholesterol Education Program Adult Treatment Panel III Guidelines. Multivariate linear 
regression models were utilized to assess associations between 25 metabolites (and the sums of 
the four categories) and serum lipid variables. Multivariate logistic regression models were applied 
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to assess associations between fecal metabolites and the four binary outcome variables. In this 
publication, most primary and secondary bile acids, as well as some plant sterols and fecal 
coprostanol and cholesterol were found to be significantly positively associated with serum lipid 
levels (especially serum triglycerides and hypertriglyceridemia). These results indicated that fecal 
bile acids may play a role in the development or progression of dyslipidemia, and suggest that this 
is an important area for future research. 
The second publication examined the relationship between habitual diet, gut microbiota 
composition, and metabolic diseases or biomarkers (BMI; waist circumference; serum LDL-c, 
HDL-c, total cholesterol, and triglycerides; T2DM; and hypertension) in the KORA FF4 study. 
Fecal microbiota composition was assessed using 16S rRNA gene amplicon sequencing, and data 
were available for 1,992 participants. Habitual dietary intake (22 food groups or subgroups, seven 
nutrients and two diet quality scores) was evaluated using repeated 24-hour food lists and one food 
frequency questionnaire. Dietary data was available for a subset of 1,442 of these individuals. 
Latent Dirichlet Allocation (LDA) was applied to learn 20 latent microbial subgroups within the 
data set, and multivariate Dirichlet regression models were used to identify associations between 
habitual diet or metabolic diseases/biomarkers and the 20 subgroups. Eight of the 20 subgroups 
were significantly associated with one or more dietary factors, and nine of the 20 subgroups were 
significantly associated with one or more metabolic disease or biomarker. Participants with a 
higher intake of foods such as fruits and whole grains were characterized with a higher probability 
for subgroups 5 and 14 in particular, while participants with T2DM had a lower probability for 
subgroups 5 and 14. This publication identified new subgroups of bacteria that may be relevant for 
metabolic diseases, and which present avenues for further research. Additionally, LDA was 
demonstrated as a powerful and effective tool for the identification of latent subgroups within 
microbiome data, with high potential for use in exploratory studies. 
The publications comprising this dissertation expand upon current knowledge of the relationship 
between diet, the gut microbiome and metabolome, and metabolic diseases. The cross-sectional 
nature of the analyses do not allow causal associations to be drawn, but were able to confirm 
previously-identified associations in a large cohort, demonstrate the application of a promising 
new machine learning method in the field, and identified important areas of study for future 





Stoffwechselerkrankungen sind sowohl in Deutschland als auch weltweit eine große 
Herausforderung für die öffentliche Gesundheit. Mit steigender Lebenserwartung und sinkenden 
Geburtenraten altert die Bevölkerung in Deutschland, was zu einem erhöhten Auftreten von 
metabolischen Erkrankungen führt. Die Ernährung ist ein wichtiger modifizierbarer Risikofaktor 
für Stoffwechselerkrankungen und steht seit Jahrzehnten im Fokus von Forschung und 
öffentlichen Gesundheitsmaßnahmen. Allerdings haben sich die offiziellen Empfehlungen über 
die Jahre hinweg geändert, und während die positiven Effekte einer präventiven 
gesundheitsförderlichen Ernährung klar zu sein scheinen, bleiben spezifische Fragen, zum Beispiel 
die Mechanismen hinter den Assoziationen zwischen Ernährung und Krankheiten, oft 
unbeantwortet. Das Darmmikrobiom und das Metabolom haben sich in den letzten Jahrzehnten zu 
einem wichtigen Forschungsschwerpunkt entwickelt, da deutlich wird, dass eine Dysbiose des 
Darmmikrobioms mit einer Reihe von menschlichen Krankheiten in Verbindung gebracht werden 
kann. Wie wichtig die Zusammensetzung und Funktion der Darmmikrobiota und ihrer 
Stoffwechselprodukte für die Stoffwechselgesundheit sind, ist jedoch nach wie vor nicht genau 
bekannt. Darüber hinaus sind viele zuvor identifizierte Assoziationen noch nicht in großen 
Kohortenstudien validiert worden. 
Diese Dissertation, die zwei begutachtete Publikationen umfasst, zielt darauf ab, neue 
Erkenntnisse über den komplexen Zusammenhang zwischen der gewöhnlichen Ernährung, dem 
Darmmikrobiom und Stoffwechselerkrankungen zu gewinnen und gleichzeitig zuvor identifizierte 
Assoziationen in einer großen, bevölkerungsbasierten Studie zu bestätigen. Die Analysen der 
beiden in der Dissertation enthaltenen Publikationen nutzen Daten der 2013/2014 durchgeführten 
Studie Kooperative Gesundheitsforschung in der Region Augsburg (KORA FF4), bei der 2.279 
Teilnehmer der ursprünglichen S4-Studie (1999-2001, n=4.261) an einer zweiten Nachbefragung 
teilnahmen.  
In der ersten Publikation wurde der Zusammenhang zwischen ausgewählten Stuhl-Metaboliten 
und Serumlipidspiegeln bei 1.387 Teilnehmern der KORA FF4-Studie untersucht. Die 
Metaboliten-Konzentrationen wurden von Metabolon Inc (Durham, NC, USA) gemessen und 
identifiziert. Aus dem Set von 807 Metaboliten wurden pflanzliche und tierische Sterole sowie 
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primäre und sekundäre Gallensäuren ausgewählt. Der Outcome Dyslipidämie wurde mit Hilfe von 
Serum-LDL-Cholesterin, HDL-Cholesterin, Gesamtcholesterin und Triglyceriden dargestellt. Alle 
vier Variablen wurden sowohl als kontinuierliche Variablen als auch als binäre Variablen 
analysiert, wobei die Cutoffs für die binären Variablen gemäß den 2003 National Cholesterol 
Education Program Adult Treatment Panel III Guidelines gewählt wurden. Multivariate lineare 
Regressionsmodelle wurden verwendet, um Assoziationen zwischen 25 Metaboliten (und den 
Summen der Kategorien pflanzliche und tierische Sterole sowie primäre und sekundäre 
Gallensäuren) und Serumlipidvariablen zu identifizeiren. Multivariate logistische 
Regressionsmodelle wurden angewandt, um Zusammenhänge zwischen Stuhl-Metaboliten und 
den vier binären Ergebnisvariablen zu modellieren. In dieser Publikation wurde festgestellt, dass 
sowohl die Mehrheit der primären und sekundären Gallensäuren als auch manche pflanzliche 
Sterole, Coprostanol und Cholesterin signifikant positiv mit den Serumlipidwerten (insbesondere 
Serumtriglyceride und Hypertriglyceridämie) assoziiert sind. Diese Ergebnisse deuten darauf hin, 
dass diese Gallensäuren eine Rolle bei der Entwicklung oder dem Fortschreiten von Dyslipidämie 
spielen können und legen nahe, dass dies ein wichtiges Gebiet für zukünftige Forschung ist. 
Die zweite Publikation untersuchte den Zusammenhang zwischen dem gewöhnlichen Verzehr, der 
Zusammensetzung der Darmmikrobiota und Stoffwechselerkrankungen oder Biomarkern (BMI, 
Taillenumfang, Serum-LDL-c, HDL-c, Gesamtcholesterin und Triglyceride, T2DM und 
Bluthochdruck) in der KORA FF4-Studie. Die Zusammensetzung der Stuhl-Mikrobiota wurde 
mittels 16S rRNA-Gen-Amplikon-Sequenzierung bestimmt, und Daten waren für 1.992 
Teilnehmer verfügbar. Die gewöhnliche Verzehr (29 Lebensmittelgruppen oder Nährstoffe und 
zwei Ernährungsqualitäts-Scores) wurde anhand von wiederholten 24-Stunden-
Nahrungsmittellisten und einem Fragebogen zur Verzehrshäufigkeit von Nahrungsmitteln 
bewertet. Ernährungsdaten waren für eine Subgruppe von 1.442 dieser Personen verfügbar. Latent 
Dirichlet Allocation (LDA) wurde angewandt, um 20 latente mikrobielle Subgruppen innerhalb 
des Datensatzes zu identifizieren, und multivariate Dirichlet-Regressionsmodelle wurden 
verwendet, um Assoziationen zwischen dem gewöhnlichen Verzehr oder 
Stoffwechselerkrankungen oder Biomarkern und den 20 Subgruppen zu identifizieren. Acht der 
20 Subgruppen waren signifikant mit einem oder mehreren Ernährungsfaktoren assoziiert, und 
neun der 20 Subgruppen waren signifikant mit einer oder mehreren Stoffwechselerkrankungen 
oder Biomarkern assoziiert. Teilnehmer mit einem höheren Verzehr von Lebensmitteln wie Obst 
17 
 
und Vollkornprodukten wurden mit einer höheren Wahrscheinlichkeit insbesondere für die 
Subgruppen 5 und 14 charakterisiert, während Teilnehmer mit T2DM eine geringere 
Wahrscheinlichkeit für die Subgruppen 5 und 14 hatten. Diese Publikation identifizierte neue 
Subgruppen von Bakterien, die für Stoffwechselerkrankungen relevant sein könnten und die 
Möglichkeiten für weitere Forschung eröffnen. Darüber hinaus wurde gezeigt, dass LDA ein 
leistungsfähiges und effektives Werkzeug für die Identifizierung latenter Subgruppen innerhalb 
von Mikrobiomdaten ist, mit hohem Potenzial für den Einsatz in explorativen Studien. 
Die in dieser Dissertation enthaltenen Publikationen erweitern den aktuellen Wissensstand über 
die Zusammenhänge zwischen Ernährung, Darmmikrobiom und Metabolom sowie 
Stoffwechselerkrankungen. Der Querschnittscharakter der Analysen erlaubt es nicht, kausale 
Schlussfolgerungen zu ziehen, konnte aber zuvor identifizierte Assoziationen in einer großen 
Kohorte bestätigen. Die Anwendung einer vielversprechenden neuen Methode des maschinellen 
Lernens auf diesem Gebiet wurde so demonstriert und wichtige Untersuchungsbereiche für 
zukünftige Forschung identifiziert.  
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